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Cardiomyopathy is a clinical problem that occurs in the hearts of type 2 diabetic
patients as well as cancer patients undergoing doxorubicin chemotherapy. The number
of diabetic cancer patients is increasing but surprisingly the cardiac damaging effects
of doxorubicin, a commonly used chemotherapeutic drug, on diabetic hearts have
not been well-examined. As the signaling mechanisms of the doxorubicin-induced
cardiomyopathy in type 2 diabetic heart are largely unknown, this study examined
the molecular signaling pathways that are responsible for the doxorubicin-induced
cardiotoxicity in type 2 diabetic hearts. Male 14- to 18-week-old db/db mice were used
as the type 2 diabetic model, and age-matched non-diabetic db/+ mice served as
controls. The db/+ non-diabetic and db/db diabetic mice were randomly assigned to the
following groups: db/+CON, db/+DOX-5d, db/+DOX-7d, db/dbCON, db/dbDOX-5d,
and db/dbDOX-7d. Mice assigned to doxorubicin (DOX) group were exposed to an
intraperitoneal (i.p.) injection of DOX at a dose of 15 mg/kg to induce cardiomyopathy.
Mice in control (CON) groups were i.p. injected with the same volume of saline instead of
DOX. Mice were euthanized by overdose of ketamine and xylazine 5 or 7 days after
the DOX injection. Microarray analysis was adopted to examine the changes of the
whole transcriptional profile in response to doxorubicin exposure in diabetic hearts.
Ventricular fractional shortening was examined as an indicator of cardiac function by
transthoracic echocardiography. The presence of diabetic cardiomyopathy in db/dbmice
was evident by the reduction of fractional shortening. There was a further impairment of
cardiac contractile function 7 days after the DOX administration in db/db diabetic mice.
According to our microarray analysis, we identified a panel of regulatory genes associated
with cardiac remodeling, inflammatory response, oxidative stress, and metabolism in
the DOX-induced cardiac injury in diabetic heart. The microarray results of selected
genes were confirmed by real time PCR. Notably, S100A8 and S100A9 were found to
have a unique specific expression pattern that was coincident with the DOX-induced
cardiomyopathy in diabetic hearts. Correspondingly, NF-κB expression in diabetic hearts
was increased together with the elevation of S100A8/9 and activation of p38 MAPK
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signaling after DOX administration, which induced cardiac inflammation as demonstrated
by the elevation of cardiac IL-6 level. These findings provide novel pre-clinical information
for revealing the S100A8/A9-associated molecular signaling pathways that mediate the
doxorubicin-induced cardiotoxicity in diabetic hearts.
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INTRODUCTION
Cancer and diabetes mellitus are two leading causes of death
in the world according to the figures reported by World
Health Organization. Epidemiological studies have evidently
demonstrated that there is a strong link between certain cancers
and type 2 diabetes mellitus (Giovannucci et al., 2010), although
the detailed mechanisms explaining the link are still unclear.
Indeed, type 2 diabetes has been shown to increase the risk
and mortality of breast, liver, colorectal, and pancreatic cancers
(Cannata et al., 2010). Thus, it is not uncommon to see the
diagnosis of both cancer and diabetes in the same individual. As
the number of people suffering from type 2 diabetes is predicted
to be rapidly increasing in the coming decades, it is expected that
the number of diabetic cancer patients will also be considerably
increasing.
Cancer patients with long standing diabetic cardiomyopathy
may present a difficult situation of cancer treatment using
chemotherapy. This is attributed to the fact that most of the
chemotherapeutic agents cause severe side effects on major vital
organs, such as the cardiotoxicity caused by doxorubicin (DOX).
DOX is extensively used for treating various cancers, such as
breast, stomach, lung, and bladder cancers (Rahman et al.,
2007). However, DOX induces life-threatening cardiomyopathy
and irreversible cardiac damage (Swain et al., 2003). Chronic
conditions, such as diabetes and previous heart disease showed
an increased risk of DOX-induced cardiomyopathy (Octavia
et al., 2012). Cardiac metabolism is critical in maintaining
the myocardial function. In the adult normal heart, 50–70%
ATP was obtained from β-oxidation of fatty acids (Lopaschuk
et al., 2010), and the remainder being primarily derived from
carbohydrate (glucose and lactate) oxidation (Jaswal et al., 2011).
However, diabetic hearts showed the increased rates of fatty
acid β-oxidation and decreased utilization of glucose (Barsotti
et al., 2009; Lopaschuk et al., 2010). Furthermore, defective β-
oxidation of fatty acids followed by energy depletion was thought
to account for the toxicity of adriamycin in cardiomyocytes
(Sayed-Ahmed et al., 2000). In addition, an in vivo study found
that the accumulation of DOX in the hearts of streptozotocin
(STZ)-induced diabetic rats was higher when compared with
non-diabetic hearts (Al-Shabanah et al., 2000). It is reasonable to
expect that a cancer patient with diabetic cardiomyopathy would
be more susceptible to the DOX-induced cardiac damage due to
the pre-existing cardiac dysfunction in the diabetic heart.
Currently, the molecular mechanisms underlying the DOX-
induced cardiotoxicity in diabetic hearts are largely unknown. It
is not clear whether the molecular signaling events that mediate
the cardiac toxic effects of DOX on the hearts of diabetic
individuals are different from that of non-diabetic individuals.
Earlier efforts have proposed a correlation between reduced
tissue accumulation of homocysteine and improved cardiac
systolic function of diabetic animals treated with peroxisome
proliferator-activated receptor gamma (PPAR-γ) agonists (Rocic
et al., 2006). Considering the role of homocysteine to promote
the assembly of NADPH oxidase associated with endothelial
injury (Becker et al., 2005), it is conceivable that DOX might
provoke hyperactivation of pro-inflammatory markers in the
diabetic myocardium with undefined mechanisms. These pieces
of information are essential for developing effective preventive
measures and therapeutic strategies to address this complicated
clinical situation that occurs in diabetic cancer patients. Thus,
this study aimed to investigate the DOX-induced cardiotoxicity
in type 2 diabetic hearts. The experiments were designed to
distinguish the signaling mechanisms responsible for the DOX-
induced cardiotoxic effects on the hearts between diabetic and
non-diabetic mice.
METHODS
Animals
Male 14- to 18-week-old C57BL/KsJ-db/dbmice (leptin receptor-
deficient transgenic mice which is a well-established animal
model of type 2 diabetes mellitus) obtained from the Laboratory
Animal Services Centre of The Chinese University of Hong Kong
were used in this study. Age-matched non-diabetic db/+ mice
with similar genetic background [C57BL/KsJ(+/+)] to db/db
mice were used as the non-diabetic control. Mice were housed
in a temperature—and humidity-controlled environment and
were exposed to a 12:12-h light:dark cycle in the Centralized
Animal Facilities of The Hong Kong Polytechnic University.
Mice were allowed to have access to standard animal diet and
water ad libitum. Animal ethics approval (ASESC No. 08/16) was
obtained from the Animal Ethics Sub-committee of The Hong
Kong Polytechnic University.
Experimental Protocol
Experiment 1: To understand the gene expression profile of the
diabetic hearts in response to acute DOX treatment, diabetic
(db/db) mice in DOX group were exposed to DOX (Pharmacia
and Upjohn SpA, Milan, Italy) at a single dose of 15 mg/kg
via an intraperitoneal (i.p.) injection. Diabetic mice in control
groups were i.p. injected with the corresponding amount of
saline instead of DOX based on the body weight. Mice were
euthanized by overdose of ketamine and xylazine 5 days after the
administration of DOX. Hearts were immediately removed and
washed with cold phosphate buffered saline (PBS). Left ventricle
was quickly dissected and frozen in liquid nitrogen and stored at
−80◦C for later microarray analysis.
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Experiment 2: To further reveal the changes of gene
expression and the underlying mechanisms in diabetic hearts in
response to DOX treatment, mice were treated likewise as in
Experiment 1 but sacrificed 5 or 7 days after the administration
of DOX. In brief, non-diabetic (db/+) and diabetic (db/db) mice
were randomly assigned to the following groups: db/+CON,
db/+DOX-5d, db/+DOX-7d, db/dbCON, db/dbDOX-5d, and
db/dbDOX-7d (n = 6 in each group). Mice in control groups
were i.p. injected with the corresponding amount of saline
instead of DOX based on the body weight. Mice were euthanized
by overdose of ketamine and xylazine 5 or 7 days after the
administration of DOX. Left ventricle was quickly dissected and
frozen in liquid nitrogen and stored at −80◦C for the later
molecular analysis.
RNA Extraction and Microarray Analysis
Forty micrograms of frozen ventricular tissues were minced and
homogenized in ice-cold TriReagent (Molecular Research Center,
USA). The tissue homogenate was then processed to separation
of the aqueous and organic phases. The RNA in the aqueous
phase was precipitated by addition of isopropanol followed by
washing with 75% ethanol. The extracted RNA pellets were then
re-suspended in DEPC-treated water. RNA concentrations were
quantified in triplicate using the optical density (OD) at 260 nm.
In this study, the technique of microarray analysis was adopted to
examine the changes of whole transcriptional profile in response
to the administration of DOX in diabetic heart. RNA samples
extracted from the ventricular tissues of mice in db/dbCON
and db/dbDOX groups 5 days after the DOX administration
were used in the microarray analysis. RNA samples (3 µg)
from the hearts of two mice in each group were pooled to
generate four biological replicates in db/dbCON and db/dbDOX
groups. The RNA quantity and quality were assessed before
microarray analysis. RNA quantity was detected by NanoDrop
1000 Spectrophotometer. The purity of RNA was assured by
examining the OD260/280 ratio. The RNA integrity was assessed
by Agilent 2100 bioanalyzer by following the manufacturer’s
instruction. In the present study, our RNA samples used for array
hybridization showed satisfactory integrity with intact bands
corresponding to 18 and 28 S ribosomal RNA and the RNA
Integrity Number (RIN) was >7.
Microarray analysis was performed using the Agilent Service
Platform with Agilent two-color mouse 4 × 44 k microarray
slides. Samples from the DOX-treated diabetic mice (db/dbDOX)
were labeled by Cy5 dye (red channel) whereas samples from
diabetic control mice (db/dbCON) were labeled by Cy3 dye
(green channel). Five hundred nanograms of Cy3-labeled and
Cy5-labeled cRNA were mixed and incubated with the Agilent
microarray slide (G2519F) for 17 h at 65◦C in the dark. Slide was
washed and scanned using an Agilent DNA microarray scanner.
Raw data were obtained using Agilent’s Feature Extraction
10.7 Software. Further analysis of the raw data was performed
by ArrayTrack comprehensive R—and Bioconductor-based web
service for microarray data analysis. Several normalizations
were performed for the pre-processing of the raw data and
these included background correction by subtraction method,
removal of dye bias by lowess normalization and multiple testing
correction by BH adjusted P-values for the Benjamini and
Hochberg step-up FDR controlling procedure (Benjamini and
Hochberg, 1995). Gene expression values were calculated by log
base 2 ratio of red channel intensity (mean), and green channel
intensity (mean). Functional pathways of highly regulated genes
were analyzed by MetaCore R© (Version 6) from GeneGo Inc.
Real Time Quantitative PCR Analysis
The transcript levels of target genes from microarray analysis in
cardiac muscles were validated by quantitative RT-PCR analysis.
Reverse transcription was performed with the PrimeScript
TM
RT reagent Kit with gDNA Eraser (Takara, Japan) according
to the manufacturer’s recommendation. One micro litter of
the diluted cDNA templates was added to reaction mixtures
containing 12.5µl FastStart Universal SYBR green master (ROX)
(Roche Diagnostics, USA), forward and reverse primers and
RNase/DNase-free water. The sequences of primers used in real
time PCR were shown in Table 1. These mixtures were carried
out in the ABI 7500 thermal cycler system followed by a two-
step cycling protocol as described previously (Pei et al., 2015).
Relative expression ratios were calculated as ratio of the target
gene normalized to expression of the internal control β-tubulin
gene.
Echocardiographic Assessment
Cardiac function was assessed before as well as 5 or 7 days
after the DOX administration by transthoracic echocardiography
by following the procedure described previously (Siu et al.,
2007). Animals were anesthetized with ketamine HCl and the
echocardiographic images were obtained during the heart rate
stabilized at ∼500 beats per minute. Ultrasound scanning was
performed by Esaote MyLab 70 X-Vision Ultrasound System
(Esoate, Italy). Using two-dimensional B-mode and M-mode
ultrasonography, left ventricle (LV) end-diastolic, end-systolic
dimensions (LVEDD and LVESD), anterior and posterior wall
thickness and heart rate were measured according to the leading-
edge method of the American Society of Echocardiography
(Lang et al., 2006). LV systolic function represented as fractional
shortening (FS) and ejection fraction (EF) were calculated by the
equation of FS (%)= [(LVEDD− LVESD) / LVEDD]× 100 and
EF (%) = Y + [(100 − Y) × 0.15], where Y = [(LVEDD2 −
LVESD2) / LVEDD2]× 100 (Dittoe et al., 2007).
Protein Fraction Preparation
Protein fractions were extracted from cardiac muscle
homogenates as described previously (Siu et al., 2004, 2005).
Forty milligrams of frozen hearts were minced and homogenized
with a Polytron in ice-cold lysis buffer (10mM NaCl, 1.5mM
MgCl2, 20 mM HEPES, pH 7.4, 20% glycerol, 0.1% Triton
X-100, and 1mM dithiothreitol). The homogenates were then
centrifuged at 875 × g for 5 min at 4◦C. The supernatant was
collected and subject to further centrifugation three times at 3500
× g for 5 min at 4◦C. After the last centrifugation, supernatant
was collected as the cytoplasmic protein fraction. This protein
fraction with the addition of protease inhibitor (P8340, Sigma-
Aldrich) was used in the Western blot analysis and cardiac
IL-6 measurement by ELISA. The protein concentrations were
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TABLE 1 | Sequence of primer used in real time PCR analysis.
Gene Gene full name GenBank Forward primer Reverse primer
accession No.
S100a8 S100 calcium binding
protein A8 (calgranulin A)
NM_013650 5′TGCCCTCTACAAGAATGACT3′ 5′AAGCTCTGCTACTCCTTGTG3′
S100a9 S100 calcium binding
protein A9 (calgranulin B)
NM_009114 5′CGACACCTTCCATCAATACT3′ 5′TCAGCATCATACACTCCTCA3′
Il7 Interleukin-7 NM_008371 5′CGCAAGTTGAGGCAA TTTCT3′ 5′ TTCCTTGCTTGTGCAGTTCA 3′
Il2r Interleukin-2 receptor NM_008368 5′CTGGAGCCTGTCCCTCTACGTCTTCC 3′ 5′GACCTGGGAGACCTTCCA GCTTATG3′
Mmp9 Matrix metallopeptidase 9 NM_013599 5′TCCAGTACCAAGACAAAGCC 3′ 5′TGA AGCAAA GAAGGAGCCC3′
Mmp8 connective tissue growth
factor
NM_008611 5′GGTAACTAACTCTGCAGCCCTCTT3′ 5′CGA ACCAGGGACGGA ATATG3′
Wnt5a Wingless-type MMTV
integration site family,
member 5A
NM_009524 5′TCCGGACTACTGTGTGC3′ 5′AGCAGCACCAGTGAA AC3′
Col1a2 Collagen, type I, alpha 2 NM_007743 5′TGAAGTGGGTCTTCCAGGTCTTTC3′ 5′CACCCT TGTTACCGGATTCTCCTT3′
Gsta2 Glutathione S-transferase,
alpha 2
NM_008182 5′CCCCTTTCCCTCTGCTGAAG3′ 5′TGCAGCCAC ACT AAA ACTTGA AAA3′
Car3 carbonic anhydrase 3 NM_007606 5′GCTCTGCTAAGACCATCC3′ 5′ATTGGCGAAGTCGGTAGG3′
Glp2r Glucagon-like peptide 2
receptor
NM_175681 5′TCATCTCCCTCTTCTTGGCTCTTAC3′ 5′TCTGACAGATATGACATCCATCCA C3′
Fabp6 Fatty acid binding protein NM_008375 5′ACGTGATTGAAAGGGGACGTAACTT3′ 5′CATTCTTTGCCA ATGGTGAACTTGT3′
Gys2 Glycogen synthase 2 NM_145572 5′CCAGCTTGACAAGTTCGACA3′ 5′ATCAGGCTTCCTCTTCAGCA3′
Igfbp5 Insulin-like growth factor
binding protein 5
NM_010518 5′GTTACCCCGCCTCTCTTCC3′ 5′TGTCTGAACGTA ACACTATAGAGAGC3′
Ptpn1 Protein tyrosine
phosphatase,
non-receptor type 1
NM_011201 5′CGGCTATTTACCAGGACATTC3′ 5′TGCGGTTGAGCATGACCAC3′
E2f2 E2F transcription factor 2 NM_177733 5′ACGGCGCAACCTACAAAGAG3′ 5′GTCTGCGTGTAAAGCGAAGT3′
Sgsm1 Small G protein signaling
modulator 1
NM_172718 5′ATGGAGGTGTCCAGCCTGAGAT3′ 5′TGGTTTGTGCGTAGCAGGCATG3′
Ube2c Ubiquitin-conjugating
enzyme E2C
NM_026785 5′GGTGACAAAGGAATCTCCGCCT3′ 5′GGGAGAGTTTGTACCTCA GGTC3′
β-tubulin Tubulin, beta NM_011655 5′CCGGACAGTGTGGCAACCAGATCGG3′ 5′TGGCCAAAAGGACCTGAGCGAACGG3′
detected in duplicate by Bradford assay (Coomassie Protein
Assay, Pierce).
Western Blot Analysis
Denatured proteins were separated by 10% SDS-PAGE gel and
transferred to polyvinylidene difluoride (PVDF) membranes
(Immobilon P, Millipore) by using the Bio-Rad Mini Protein
II system. Membranes were subsequently blocked by 5%
non-fatty milk in PBS with 0.1% Tween-20 (PBST) for 1 h
and probed with antibodies against S100A8 (1:500 dilution,
Santa Cruz Biotechnology), S100A9 (1:500 dilution, Santa
Cruz Biotechnology), phospho-p38 (1:1000 dilution, Cell
Signaling Technology), p38 (1:1000 dilution, Cell Signaling
Technology), NF-κB (1:500 dilution, Santa Cruz Biotechnology),
phospho-ERK1/2 (1:1000 dilution, Cell Signaling Technology),
ERK1/2 (1:1000 dilution, Cell Signaling Technology), phospho-
Akt (1:1000 dilution, Cell Signaling Technology), and Akt
(1:1000 dilution, Cell Signaling Technology) overnight at 4◦C.
Membranes were then incubated with appropriate secondary
antibodies [anti-mouse IgG or anti-rabbit IgG horseradish
peroxidase (HRP)-conjugated antibodies (1:5000 dilution, Cell
Signaling Technology)] after washing for 1 h. Immunolabeled
bands were visualized by the ECL chemiluminescence reaction
kit (Perkin Elmer), and captured by Kodak 4000R Pro camera
system. Measurement of β-tubulin (1:2000 dilution, Sigma) was
included as the internal control reference. The arbitrary units
of the blot signal were determined by Image J software and
presented as net intensity x band area.
Measurement of Cardiac IL-6 by ELISA
Tissue lysates from ventricular samples were used for the
measurement of IL-6 concentration using an ELISA kit (Abcam)
according to the manufacturer’s instruction. In brief, 10-fold
diluted ventricular lysates were added to the reaction wells
and incubated overnight at 4◦C with gentle shaking. After four
times of washing, samples were incubated with biotinylated IL-
6 detection antibody for 1 h at room temperature followed by
sequent reaction with HRP-streptavidin and one-step substrate
reagent. With the addition of stop solution, the intensity of
sample reaction was measured at 450 nm. Sample concentration
of IL-6 was calculated according to the standard curve generated
from the provided standard solutions.
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Statistical Analysis
Statistical analysis was performed by using the Statistics Package
for Social Science (SPSS) version 11.0. All data were expressed as
mean ± standard error of mean (SEM). Two-way ANOVA was
used to examine the interaction and main effect(s) of the two
experimental factors (i.e., diabetes and DOX). The details of two-
way ANOVA (P-value, F) were provided in the figure (on the
top of the figures). When significant differences were observed,
statistical comparisons among groups were performed with one-
way ANOVA with Tukey’s HSD post-hoc test. The results of one-
way ANOVA were shown in the figure (between the columns).
P < 0.05 was accepted to be statistically significant.
RESULTS
Whole Transcriptional Profile Following
DOX Exposure in Diabetic Heart
Gene expression profiles in left ventricular muscle of diabetic
mice with and without DOX administration were examined by
microarray analysis. In our analysis, only those genes with the
transcriptional level changes of 2-fold or higher were identified
as significantly regulated. According to our criteria, a total of
709 genes were significantly affected by DOX administration
in db/db diabetic heart. Of these, 408 genes were up-regulated
and 301 genes were down-regulated by DOX in db/db diabetic
heart. Selected gene expressions with significant alteration
and the qRT-PCR validation results were shown in Table 2.
Furthermore, the significantly regulated genes were selected for
further pathway analysis by MetaCore R© (Version 6). The top 10
scored pathways (the pathway map with the lowest P-value) were
identified and presented in Table 3.
Animal Survival Analysis
The animal survival rates of db/+CON (non-diabetic control,
n = 20), db/dbCON (diabetic control, n = 20), db/+DOX (non-
diabetic with DOX administration, n = 20) and db/dbDOX
(diabetic with DOX administration, n = 20) were analyzed by
Kaplan-Meier approach (Figure 1). As expected, DOX reduced
the survival of both db/+ non-diabetic mice and, db/db type 2
diabetic mice (db/+DOX vs. db/+CON, 60 vs. 100%, P < 0.01;
db/dbDOX vs. db/dbCON, 10 vs. 100%, P < 0.001; Figure 1).
However, it is noteworthy that the survival rate of diabetic mice
was much lower in comparison with its non-diabetic littermates
7 days after the injection of DOX (35 vs. 75%, P < 0.001);
this observation was found to be more prominent 14 days after
administration (10 vs. 60%, P < 0.001).
Cardiac Functional Assessment
Cardiac function was measured non-invasively in non-diabetic
and diabetic mice. The representative echocardiograhic M-
mode images were shown in Figure 2. DOX induced cardiac
TABLE 2 | Significantly regulated genes in response to DOX in diabetic heart (diabetes saline control vs. diabetes 5 days after DOX).
Gene name Microarray (n = 8) qRT-PCR (n = 8)
P-value Fold change Regulation P-value Fold change Confirmed
INFLAMMATORY/IMMUNE RESPONSE
S100 calcium binding protein A8 (calgranulin A) 0.017 5.89 up 0.039 2.82 yes
S100 calcium binding protein A9 (calgranulin B) 0.028 4.08 up 0.09 6.67 yes
Tumor necrosis factor receptor superfamily, member 13c 0.002 2.17 up 0.007 1.62 yes
Interleukin 7 0.004 3.02 up 0.38 1.17 no
Interleukin 2 receptor, gamma chain 0.015 0.45 down 0.68 0.87 no
CARDIAC REMODELING AND MATRIX
Matrix metallopeptidase 9 0.04 2.62 up 0.003 1.86 yes
Matrix metallopeptidase 8 0.016 3.21 up 0.011 4.51 yes
Collagen, type I, alpha 2 0.002 0.43 down 0.31 0.86 no
Wingless-related MMTV integration site 5A 0.002 0.48 down 0.01 0.58 yes
OXIDATIVE STRESS RELATED
Glutathione S-transferase, alpha 2 (Yc2) 0.0004 3.27 up 0.038 1.69 yes
Carbonic anhydrase 3 0.047 0.4 down 0.012 0.72 yes
METABOLISM
Glucagon-like peptide 2 receptor 0.03 3.48 up 0.036 1.72 yes
Fatty acid binding protein 6 0.03 3.31 up 0.018 4.46 yes
Glycogen synthase 2 0.04 2.55 up 0.60 0.84 no
Akt AND ERK SIGNALING
Protein tyrosine phosphatise, non-receptor type 1 0.03 2.02 up 0.031 1.53 yes
SIGNAL TRANSDUCTION/TRANSCRIPTION PROTEIN
E2F transcription factor 2 0.041 0.45 down 0.004 0.25 yes
Ubiquitin-conjugating enzyme E2C 0.008 0.48 down 0.26 0.89 no
Small G protein signaling modulator 1 0.0005 0.42 down 0.119 0.76 no
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dysfunction in db/+ non-diabetic mice 5 days after the
administration of DOX as illustrated by a significant reduction
of cardiac fractional shortening from 80.9 to 62.4% (P < 0.05,
Table 4). Cardiac dysfunction resulted from type 2 diabetes
was evident by observing a significant decrease in fractional
shortening from 81.5% in db/+ non-diabetic mice to 65.7%
in diabetic db/db mice at baseline (P < 0.05). However, a
further decrease in fractional shortening was not observed in
db/db diabetic mice 5 days after the administration of DOX.
TABLE 3 | Top 10 pathway maps by MetaCore® analysis in diabetic heart 5
days following DOX.
Number Enriched pathway maps P-value Genes in
our data
1 Cell adhesion_ECM remodeling 1.693E-04 4
2 Transcription_Role of AP-1 in regulation of
cellular metabolism
1.102E-03 3
3 Immune response_IL-13 signaling via
JAK-STAT
1.691E-03 3
4 Transcription_Androgen Receptor nuclear
signaling
1.085E-03 3
5 Immune response_MIF-mediated
glucocorticoid regulation
6.201E-03 2
6 Cell adhesion_Endothelial cell contacts by
non-junctional mechanisms
7.358E-03 2
7 Proteolysis_Role of Parkin in the
Ubiquitin-Proteasomal Pathway
7.358E-03 2
8 Immune response_Antigen presentation
by MHC class I
9.940E-03 2
9 Development_Hedgehog and PTH
signaling pathways in bone and cartilage
development
1.612E-02 2
10 Cytoskeleton remodeling_Cytoskeleton
remodeling
1.762E-02 3
Nonetheless, DOX was found to significantly induce a further
impairment of cardiac contractile function in db/db diabetic mice
when compared to db/+ non-diabetic mice 7 days after the DOX
administration as indicated by a decrease in fractional shortening
from 67.3 to 40.3% in the db/db diabetic mice treated with DOX
(P < 0.05, Table 4). Ejection fraction showed a similar changing
pattern with fractional shortening as illustrated by a significant
7.4% decrease in diabetic mice at baseline and a further reduction
in diabetic mice 7 days following DOX administration (Table 4).
Body Weight Loss in Diabetic and
Non-diabetic Mice after DOX Treatment
Adult db/db diabetic mice are remarkably obese compared to
their non-diabetic control. Following the DOX treatment, there
were significant body weight loss in both db/db diabetic and db/+
non-diabetic mice (Table 5). After DOX injection, themean body
weight in db/+ mice decreased from 27.4 to 23.9 g on day 5 (by
12%, P < 0.01), and to 22.8 g on day 7 (by 16%, P < 0.001).
Similar trend of body weight loss was observed in db/db diabetic
mice treated with DOX (from 47.2 to 43.1 g on day 5 and to 39.6 g
on day 7, by 8.7%, P < 0.01 and 16%, P <0.001, respectively).
However, weight loss was worse in db/db diabetic mice from day
5 to day 7 (by 8.1%) after DOX treatment than db/+ non-diabetic
mice (by 4.6%).
Alteration of Specific Gene Expressions
after DOX in Diabetic and Non-diabetic
Hearts
Significant changes of 6 genes including S100A8, S100A9,
Mmp8, Wnt5a, Fabp6, and E2f2 as demonstrated by microarray
analysis were further confirmed by real time PCR analysis.
In addition, the expression levels of these genes were further
examined in the hearts of non-diabetic and diabetic mice 5
and 7 days after the DOX administration. The db/+ non-
diabetic heart showed a low expression level of S100A8 and
FIGURE 1 | Animal survival analysis. Decreased survival rate in db/+DOX (non-diabetic mice treated with DOX, n = 20 per group), and db/dbDOX (diabetic mice
treated with DOX, n = 20 per group). *P < 0.001 compared to non-diabetic mice treated with DOX on day 7 and 14.
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FIGURE 2 | M-mode echocardiographic image. Echocardiography of doxorubicin (DOX)-treated non-diabetic and diabetic mice was performed before and after
the 5- and 7-day experimental period to assess the cardiac function. db/+CON; non-diabetic control group, db/+DOX-5d, non-diabetic mice on day 5 with treatment
of doxorubicin; db/+DOX-7d, non-diabetic mice on day 7 with treatment of doxorubicin; db/dbCON; diabetic control group, db/dbDOX-5d, diabetic mice on day 5
with treatment of doxorubicin; db/dbDOX-7d, diabetic mice on day 7 with treatment of doxorubicin.
S100A9 and no changes were observed 5 or 7 days after
DOX treatment (Figures 3A,B). Gene expression of S100A8 was
found to be significantly elevated by DOX in diabetic heart
5 days (by 2.8 fold), and 7 days (by 8.2 fold) after DOX
administration relative to the diabetic control (Figure 3A). These
data suggested that S100A8 might not be involved in DOX-
induced cardiotoxicity in non-diabetic mice but was associated
with the DOX cardiotoxicity in diabetic heart. Similarly, the
transcript level of S100A9 in the heart was increased by DOX
in db/db diabetic mice 5 days after DOX administration relative
to the diabetic control (by 6.7 fold, P < 0.01) and was further
elevated by DOX 7 days following DOX administration (by 6.9
fold, P < 0.001) when compared to the hearts harvested 5 days
after DOX administration (Figure 3B). Transcript expression
level of collagenase-2 (Mmp8) was slightly increased in db/+
non-diabetic heart 5 days after DOX administration, but this
change did not reach to statistical significance (Figure 3C).
Nonetheless, DOX induced an increase in the expression level
of Mmp8 5 days (by 4.5 fold, P < 0.05) and induced a further
increase 7 days following DOX administration (by 3.2 fold, P <
0.001) in db/db diabetic mice heart (Figure 3C). Although there
was an increased expression of Wnt5a in db/db diabetic heart
(by 3.5 fold, P = 0.016) and a reduced E2f2 expression in db/+
non-diabetic mice heart 5 days after the DOX administration (by
79%, P = 0.029; Figures 3D,E), the gene expression of Wnt5a,
Fabp6, and E2f2 were not found to be specifically regulated 7
days following DOX administration in db/db diabetic heart as
they showed similar changes as compared to the hearts collected
5 days after DOX treatment (Figures 3D–F).
Elevation of S100A8/A9 Accompanied the
Activation of p38 MAPK Signaling and
NF-κB in DOX-Treated Diabetic Hearts
Consistent with our mRNA findings, the protein abundances
of S100A8 and S100A9 in diabetic heart were significantly
up-regulated by DOX administration 7 days after DOX
administration when compared to db/db diabetic control
(Figures 4A,B). S100A8 and S100A9 have been suggested
to promote NF-κB activation through p38 MAPK signaling
pathway, and therefore, the phosphorylation of p38 and NF-κB
were further examined. The p38 MAPK signaling was activated
5 days after DOX treatment in db/+ non-diabetic hearts (by 4.2
fold, P = 0.036) when compared to non-diabetic control hearts
(Figure 4C). Although this activation of p38 MAPK signaling
was not found in db/db diabetic hearts 5 days following DOX
administration, phosphorylation of p38 MAPK was activated 7
days after DOX administration in diabetic hearts (P < 0.001,
Figure 4C). Consistently, the protein abundance of NF-κB was
increased (by 2.6 fold, P = 0.017) in the hearts of db/db diabetic
mice 7 days after DOX treatment when compared to diabetic
hearts collected 5 days after DOX administration (Figure 4D).
Cardiac Pro-survival Akt and ERK1/2
Signaling and Inflammatory Marker
Pro-survival Akt signaling was activated 5 days after DOX
administration in db/+ non-diabetic heart as indicated by an
increased ratio of phospho-Akt-to-total Akt (by 1.8 fold, P =
0.021) relative to db/+ non-diabetic control mice (Figure 5A).
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TABLE 5 | Body weight at baseline and following DOX treatment.
Time db/+ non-diabetic mice db/db diabetic mice
(days) (grams) (grams)
CON DOX CON DOX
Baseline 27.1±1.18 27.4± 0.39 45.3± 1.74* 47.2±1.49*
Day 5 26.5±1.02 23.9± 0.48** 43.3± 1.81 43.1±1.80**
Day 7 25.4±0.78 22.8± 1.39*** 42.1± 1.36 39.6±2.04***
Body weights were measured at the baseline and the 5 and 7-day experimental period in
db/+ non-diabetic and db/db diabetic mice. *P < 0.001 compared to db/+ non-diabetic
mice at the baseline; **P < 0.01 compared to the corresponding baseline (indicating
the weight loss following DOX treatment on day-5); ***P < 0.001 compared to the
corresponding baseline (indicating the weight loss following DOX treatment on day-7).
This increase was not observed 7 days after DOX administration
in the db/db diabetic mice (Figure 5A). However, db/db diabetic
mice 5 days after DOX administration showed a suppression of
cardiac Akt signaling (by 49.2%, P = 0.034) when compared to
diabetic control mice (Figure 5A). DOX did not induce further
suppression of the Akt phosphorylation in diabetic heart 7 days
after DOX administration (Figure 5A). No significant changes
were seen in ERK1/2 signaling in the hearts of mice among all
groups (Figure 5B).
Inflammatory process has been suggested to be involved
in the development of S100A8- and S100A9-mediated cardiac
dysfunction, and thus the concentration of cardiac IL-6 was
examined. IL-6 level in the hearts of db/+ non-diabetic mice
was not found to be significantly changed among all groups
(Figure 6). However, in the hearts of db/db diabetic mice, there
was a significant elevation of cardiac IL-6 level 7 days after DOX
treatment (P= 0.032) relative to diabetic control mice (Figure 6).
DISCUSSION
Doxorubicin (DOX) is an effective chemotherapeutic agent for
treating many types of cancers including leukemia, cancers of
bladder, breast, stomach, and lung. Given that the clinical use of
DOX is often accompanied by the development of cardiac failure,
its therapeutic value in patients with concomitant presentation
of type 2 diabetes is thought to be severely compromised due
to the possible aggravation of pre-existing cardiac complications.
The acute cardiotoxicity of DOX is considered to be mediated
by apoptosis, fibrosis, oxidative stress, and metabolic remodeling
(Childs et al., 2002; Suliman et al., 2007; Takemura and Fujiwara,
2007; Yang et al., 2015). Our previous data also showed that DOX
induced cardiac dysfunction and apoptosis in non-diabetic mice
(Pei et al., 2014). Nonetheless, it is not clear how the diabetic
heart is being affected by DOX and these pieces of information
are necessary for the exploration of effective strategies to protect
the hearts of type 2 diabetic cancer patients undergoing DOX
therapy.
In the present study, we hypothesized that the diabetic
hearts would be more susceptible to the DOX-induced toxicity
compared with non-diabetic hearts. Not only we showed that
the basal ventricular fractional shortening was lower in db/db
diabetic mice compared with its db/+ non-diabetic littermates,
Frontiers in Physiology | www.frontiersin.org 8 August 2016 | Volume 7 | Article 334
Pei et al. Doxorubicin-Induced Cardiotoxicity in Diabetic Heart
FIGURE 3 | Transcript expressions of selected genes from microarray results. The transcript expressions of S100A8 (A), S100A9 (B), Mmp8 (C), Wnt5a (D),
Fabp6 (E), and E2f2 (F) were examined by real time RT-PCR. Data are presented as expression ratio normalized to β-tubulin gene. Data are expressed as mean ±
SEM (n = 6 per group). Two-way ANOVA indicated a significant interaction effect between the two experimental factors (i.e., diabetes and DOX treatment) in S100A8
(P < 0.001, F = 41.74), S100A9 (P < 0.001, F = 54.822), and Mmp8 (P = 0.004, F = 7.495; A–C). A significant main effect of the factor diabetes was found in
Wnt5a (P = 0.023, F = 5.783; D). A significant main effect of the factor DOX treatment was found in Fabp6 (P = 0.005, F = 6.222), and E2f2 (P = 0.002, F = 7.74;
E,F). Individual means were compared among groups by one-way ANOVA with Turkey’s HSD post-hoc test.
an observation consistent with previous reports (Belke et al.,
2004), we have also demonstrated for the first time that this
spontaneous reduction in db/db mice was further exacerbated
with a dramatic drop of survival rate 7 days after DOX
administration. This observation led to the speculation that the
molecular mechanisms by which DOX induces cardiotoxicity
under diabetic condition were distinct from its counterparts with
functional glycemic control. Here, our microarray analyses have
unraveled 12 differentially regulated genes including S100A8,
S100A9, and Mmp8. in type 2 diabetic hearts challenged with
DOX. These data were further validated with quantitative real-
time RT-PCR showing consistent findings. Furthermore, our
MetaCore R© analysis revealed that the significantly regulated
genes were related to the regulation of cell adhesion (extracellular
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FIGURE 4 | Cardiac inflammatory pathway. The protein abundances of S100A8 (A), S100A9 (B), phospho-p38, total p38 (C), and NF-κB (D) in the hearts were
examined by Western blot. Densitometric quantification was performed and data are presented as net intensity x resulting band area and expressed in arbitrary units.
Results are normalized to corresponding β-tubulin signal. Data are expressed as mean ± SEM. According to our two-way ANOVA results, a significant interaction
effect between the two experimental factors (i.e., diabetes and DOX treatment) was found in S100A9 (P = 0.012, F = 5.339; B) and phosphorylation of p38 MAPK (P
< 0.001, F = 15.832; C). A significant main effect of the factor diabetes was found in S100A8 (P = 0.007, F = 8.871; A). A significant main effect of the factor DOX
treatment was found in NF-κB (P < 0.001, F = 11.712; D). Individual means were compared among groups by one-way ANOVA with Turkey’s HSD post-hoc test.
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FIGURE 5 | Myocardial pro-survival cellular signaling. Activation of Akt
and ERK1/2 signaling was determined by examining their phosphorylation
statuses. Protein abundances of phospho-Akt, total Akt, phospho-ERK1/2,
total ERK1/2 were measured by Western blot analysis. Phospho-Akt-to-total
Akt (A), and phospho-ERK1/2-to-total ERK1/2 (B) were shown. Data are
expressed as mean ± SEM. According to our two-way ANOVA results, a
significant interaction effect between the two experimental factors (i.e.,
diabetes and DOX treatment) was found in the ratio of phospho-Akt-to-total
Akt (P = 0.01, F = 5.503; A). Individual means were compared among groups
by one-way ANOVA with Turkey’s HSD post-hoc test.
matrix remodeling), transcription of AP-1 in regulation of
cellular metabolism, immune response of IL-13 signaling via
the JAK/STAT pathway, and transcriptional event of androgen
receptor nuclear signaling.
S100 calcium binding protein A8 (S100A8), and A9 (S100A9)
are members of the S100 family implicated in inflammatory
response and immune diseases (Belke et al., 2004; Ehrchen et al.,
2009). Recent human studies have suggested that S100A8/A9
levels were elevated in type 2 diabetic patients (Peterson, 2002;
Ortega et al., 2012) and indeed, the S100A8/S100A9 complex
FIGURE 6 | Cardiac IL-6. Concentration of IL-6 in the hearts was examined.
Data are expressed as mean ± SEM. According to our two-way ANOVA
results, the significant main effects of the factor diabetes and DOX were found
in IL-6 concentration (Diabetes effect: P = 0.008, F = 8.144; DOX effect: P =
0.035, F = 3.827). Individual means were compared among groups by
one-way ANOVA with Turkey’s HSD post-hoc test.
could be an useful biomarker for the prediction of 1-year
mortality in elderly patients with severe heart failure (Ma et al.,
2012). Moreover, an in vivo study showed that the activation
of S100A8/A9 was crucial for the development of post-ischemic
heart failure via the innate immune receptors including receptor
of advanced glycation end products (RAGE), and toll-like
receptor 4 (TLR4) (Harja et al., 2008; Volz et al., 2012). Notably,
the expression of S100A8 and S100A9 was increased abruptly at
both transcript and protein levels in diabetic hearts 7 days after
DOX challenge. Previous reports have shown that the cardiac
overexpression of S100A8/A9 was associated with decreased
calcium flux and ejection fraction (Boyd et al., 2008) whereas
knockdown of S100A9 ameliorated the lipopolysaccharide-
induced cardiac dysfunction (Boyd et al., 2008). Furthermore,
administration with a S100A9-neutralizing antibody was found
to prevent the activation of NF-κB, inflammatory cell infiltration,
cytokine production, subsequent perivascular and interstitial
fibrosis, and hypertrophy in the heart induced by angiotensin II
infusion (Wu et al., 2014). Taken together, our novel data suggest
that pharmacological blockade of S100A8/A9 may represent
a promising cardioprotective strategy in cancer patients with
history of diabetes, thus restoring the therapeutic value of
doxorubicin in these patients.
Next, we investigated the mechanisms that are related to
S100A8 and S100A9 for the detrimental effects of DOX in
diabetic hearts. The effects of S100A8/A9 on the downstream
signaling were shown to be varied in different models. For
instance, p38 MAPK and ERK1/2 was shown to be activated
and suppressed, respectively, following the binding of S100A8/A9
to RAGE in gastric cancer cells (Kwon et al., 2013) whilst
in colon cancer cells, S100A8/A9 induced the activation of
ERK1/2 and JNK but not p38 MAPK (Ichikawa et al., 2011).
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FIGURE 7 | Distinct mechanism of doxorubicin-induced toxicity in diabetic hearts. Doxorubicin (DOX) up-regulates S100A8/A9 and increases the expression
of IL-6, which is a pro-inflammatory cytokine, in the diabetic heart through the p38 MAPK/NF-κB axis. It is noteworthy that these observations were not made with
non-diabetic hearts subject to DOX challenge.
While S100A8/A9-RAGE binding increased the activities of p38
MAPK, JNK, ERK1/2, and NF-κB in isolated ventricles from a
murine model of post-ischemic heart failure (Volz et al., 2012),
S100A8/A9 failed to activate Akt/ERK signaling and subsequent
inflammation and fibrosis in necrotic myocardial cells of TLR4-
deficient mice (Zhang et al., 2015). This is the first attempt
reporting that S100A8/A9 elevated the phosphorylation level of
p38MAPK in the heart of db/db diabetic mice. In agreement with
the critical role of ERK1/2, but not p38 MAPK, in the promotion
of cardiac hypertrophy (Peterson, 2002; Rose et al., 2010; Asrih
et al., 2013), neither did doxorubicin provoke the activation of
ERK1/2 nor development of hypertrophy in diabetic hearts. More
prominently, the induction of p38 signaling was known to trigger
the release of pro-inflammatory cytokines including IL-6, TNFα,
and IL-1β through the action of NF-κB (Rose et al., 2010; Schiopu
and Cotoi, 2013; Simard et al., 2013; Gao et al., 2015). Provided
that NF-κB mediated the pro-inflammatory effects ofS100A8/A9
(Vogl et al., 2012) and the suggestion of S100A8/S100A9 complex
and IL-6 as markers of prognosis in senior patients with heart
failure (Ma et al., 2012), we observed concordantly that the
protein abundances of NF-κB and IL-6 were increased in diabetic
hearts in response to DOX exposure.
Collectively, the present work is the first to reveal two
damage-associated molecular pattern (DAMP) proteins, S100A8
and S100A9, are associated with the doxorubicin-induced
cardiotoxicity in type 2 diabetic hearts. Distinct mechanism of
doxorubicin-induced toxicity in diabetic hearts was summarized
in Figure 7. We propose that the increased expression of cardiac
NF-κB and IL-6 and activation of p38 MAPK may underpin
S100A8/A9-mediated inflammation as a potential target for the
attenuation of myocardial toxicity in type 2 diabetic individuals
receiving doxorubicin therapy.
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